The natural history of Parkinson' disease

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Poewe, W H ^a   Wenning, G K ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; SELEGILINE;

COMORBIDITY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DISEASE COURSE; FOLLOW UP; HUMAN; MORTALITY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0031667288     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440703     Document Type: Conference Paper

References (59)

1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442
2. Marttila PJ, Rinne UK. Disability and progression in Parkinson's disease. Acta Neurol Scand 1977;56:159-169
3. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764
4. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348
5. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301
6. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987;7:3915-3934
7. Künzle H. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis. Brain Res 1975;88: 195-209
8. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiological and clinical implications. N Engl J Med 1988;318:876-880
9. Vidailhet M, Bonnet AM, Marconi R, Guider-Khouja N, Agid Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot? Neurology 1994;44:1613-1616
10. Parkinson J. An essay on the shaking palsy. London: Sherwood, 1817
11. Lee CS, Schulzer M, Mak E, et al. Patterns of asymmetry do not change over the course of idiopathic parkinsonism: implications for pathogenesis. Neurology 1995;45:435-439
12. The Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-1060
13. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
14. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
15. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45
16. The Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43: 318-325
17. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777
18. Lee CS, Schulzer M, Mak K, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 1994;117: 501-507
19. Bonnet AM, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542
20. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591
21. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983;2:1457-1459
22. Morrish PK. Parkinson's disease is not a long-latency illness. Mov Disord 1997;12:849-854
23. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
24. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;506:743-755
25. Gibb WRG, Lees AJ. The relevance of the lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752
26. Duvoisin RC. The genetics of Parkinson's disease: a review. In: Rinne UK, Nagatsu T, Horowski R, eds. International Workshop Berlin Parkinson's Disease. Bussum, NL: Medicom, 1991: 38-57
27. Gonera EG, van't Hof M, Berger HJC, van Weel C, Horstink MWIM. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997;12:871-876
28. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neurol Transmiss 1983;(Suppl 19):253-264
29. Wenning GK, Ben Shlomo Y, Magalhaes N, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994;117:835-845
30. Tetrud JW, Langston JW. The effect of deprenyl (selegeline) on the natural history of Parkinson's disease. Science 1989;245: 519-522
31. Lees AJ (Parkinson's Disease Research Group of the United Kingdom). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegeline in patients with early, mild Parkinson's disease. BMJ 1995;311: 1602-1607
32. Zetusky WJ, Jankowic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985;35:522-526
33. Roos RAC, Jongen CF, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996; 3:236-242
34. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology 1988;38: 1841-1844
35. Blin J, Dubois B, Bonnet AM, Vidailhet M, Brandabur M, Agid Y. Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry 1991;54:780-782
36. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989;39:1187-1190
37. Gibb WRG, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988;38:1402-1406
38. Gershanik OS, Leist A. Juvenile Parkinson's disease. Adv Neurol 1986;45:213-216
39. Lima B, Neves G, Nora M. Juvenile parkinsonism: clinical and metabolic characteristics. J Neurol Neurosurg Psychiatry 1987; 50:345-348
40. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91
41. Biggins CA, Boyd JL, Harrop FM, et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:566-571
42. Goetz CG, Stebbins GT. Risk factor for nursing home placement in advanced Parkinson's disease. Neurology 1993;43: 2227-2229
43. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671
44. Gerstenbrand F, Poewe WH. The classification of Parkinson's disease. In: Stern GM, ed. Parkinson's disease. London: Chapman and Hall, 1987:315-331
45. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson G. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377-382
46. Bennett DA, Beckett LA, Murray AM. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76
47. Nobrega FT, Glattre E, Kurland LT, Okazaki H. Comments on the epidemiology of parkinsonism including prevalence and incidence statistics for Rochester, Minnesota, 1935-1966. In: Barbeau A, Brunette JR, eds. Progress in neurogenetics. Amsterdam: Excerpta Medica, 1967:474-485
48. Kurland LT. Epidemiology: Incidence, geographic distribution and genetic considerations. In: Field WJ, ed. Pathogenesis and treatment of parkinsonism. Springfield, IL: Charles C. Thomas, 1958:5-49
49. Yahr MD. Evaluation of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Editiones Roche, 1976:435-444
50. Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson's disease. QJ Med 1980;49:283-293
51. Diamond SG, Markham CH, Hoehn MM, McDowell FI, Muenter MD. Multicenter srudy of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12
52. Curtis L, Lees AJ, Stern GM, Marmot MG. Effect of L-dopa on the course of Parkinson's disease. Lancet 1984;2:211-212
53. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County Project. Neurology 1993;43:1918-1926
54. Ebmaier YP, Calder SA, Crawford JR, Stewart L, Besson JAO, Mutch WJ. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study. Acta Neurol Scand 1990;81:294-299
55. Rajput AH, Offord KP, Beard CU, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Can J Neurol Sci 1992;19:103-107
56. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology. J Neurol Neurosurg Psychiatry 1995;58:293-299
57. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of l-deprenyl to Madopar treatment of Parkinson's disease: a long-term study. J Neural Transmiss 1985;64:113-127
58. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40: 841-845
59. Maki-Ikola O, Kilkku O, Heinonen E. Other studies have not shown increased mortality [letter]. BMJ 1996;312:702